Advertisement

Corrigendum to ‘Seizures in myelin oligodendrocyte glycoprotein antibody-associated disorders and related immune factors’ [Seizure: European Journal of Epilepsy 92 (2021) 216-220

  • Kang Liu
    Affiliations
    Department of Pediatrics, The Third Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, Hebei, China

    Department of Neurology, The Children's Hospital of Hebei Province, Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
  • Suzhen Sun
    Affiliations
    Department of Neurology, The Children's Hospital of Hebei Province, Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
  • Jieyuan Cui
    Affiliations
    Department of Nephrology and Immunology, The Children's Hospital of Hebei Province, Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
  • Lei Zhang
    Affiliations
    Department of Nephrology and Immunology, The Children's Hospital of Hebei Province, Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
  • Kai Zhang
    Affiliations
    Department of Neurology, The Children's Hospital of Hebei Province, Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
  • Lin Zhang
    Correspondence
    Corresponding author at: Department of Pediatrics, The Third Hospital of Hebei Medical University, 139 Ziqiang Road, Shijiazhuang City, Hebei Province, China.
    Affiliations
    Department of Pediatrics, The Third Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, Hebei, China
    Search for articles by this author
Published:September 03, 2022DOI:https://doi.org/10.1016/j.seizure.2022.07.009
      The authors regret that there was a mistake in the affiliation information for Kang Liu, whose affiliations should have been given as both a and b.
      The correct information is provided in the authorship details above.
      The authors would like to apologise for any inconvenience caused and confirm that this mistake does not impact the scientific conclusions of the article in any way.

      Linked Article

      • Seizures in myelin oligodendrocyte glycoprotein antibody-associated disorders and related immune factors
        Seizure - European Journal of EpilepsyVol. 92
        • Preview
          MOG was identified in the late 1970s as a central nervous system (CNS) specific protein expressed on the surface of myelin sheath and oligodendrocytes. In pediatric demyelinating diseases, MOG antibodies were first described in 2007 [1], and Mariotto [2] reported that MOG-IgG was detected in up to 40% of pediatric patients with acquired demyelinating syndromes (ADS) of the CNS. MOG antibody-mediated central nervous system demyelinating diseases have a variety of phenotypes, including optic neuritis (ON), myelitis, acute disseminated encephalomyelitis (ADEM), and brain stem/cortical encephalitis.
        • Full-Text
        • PDF
        Open Archive